
John D Lambris

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6879050/publications.pdf Version: 2024-02-01



IOHN DIAMBRIS

#	Article	IF	CITATIONS
1	Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis. Cancer Letters, 2022, 529, 70-84.	3.2	51
2	Compstatins: the dawn of clinical C3-targeted complement inhibition. Trends in Pharmacological Sciences, 2022, 43, 629-640.	4.0	31
3	Application of the C3 inhibitor compstatin in a human whole blood model designed for complement research – 20 years of experience and future perspectives. Seminars in Immunology, 2022, 59, 101604.	2.7	5
4	Bothrops jararaca Snake Venom Inflammation Induced in Human Whole Blood: Role of the Complement System. Frontiers in Immunology, 2022, 13, .	2.2	5
5	C3-targeted host-modulation approaches to oral inflammatory conditions. Seminars in Immunology, 2022, 59, 101608.	2.7	9
6	Complement component C3: A structural perspective and potential therapeutic implications. Seminars in Immunology, 2022, 59, 101627.	2.7	23
7	Considering innate immune responses in SARS-CoV-2 infection and COVID-19. Nature Reviews Immunology, 2022, 22, 465-470.	10.6	14
8	Complement C3 activation in the ICU: Disease and therapy as Bonnie and Clyde. Seminars in Immunology, 2022, 60, 101640.	2.7	2
9	Emerging opportunities for C3 inhibition in the eye. Seminars in Immunology, 2022, 59, 101633.	2.7	5
10	Targeting complement components C3 and C5 for the retina: Key concepts and lingering questions. Progress in Retinal and Eye Research, 2021, 83, 100936.	7.3	37
11	CD14 inhibition improves survival and attenuates thromboâ€inflammation and cardiopulmonary dysfunction in a baboon model of Escherichia coli sepsis. Journal of Thrombosis and Haemostasis, 2021, 19, 429-443.	1.9	16
12	Response to "Comment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19― Clinical Immunology, 2021, 222, 108617.	1.4	0
13	Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression. Nature Cancer, 2021, 2, 218-232.	5.7	34
14	C5a-C5aR1 Axis Activation Drives Envenomation Immunopathology by the Snake Naja annulifera. Frontiers in Immunology, 2021, 12, 652242.	2.2	8
15	Complement mediates binding and procoagulant effects of ultralarge HIT immune complexes. Blood, 2021, 138, 2106-2116.	0.6	23
16	Is complement the culprit behind COVID-19 vaccine-related adverse reactions?. Journal of Clinical Investigation, 2021, 131, .	3.9	25
17	Serum amyloid P component is an essential element of resistance against Aspergillus fumigatus. Nature Communications, 2021, 12, 3739.	5.8	18
18	Erythrocytes identify complement activation in patients with COVID-19. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L485-L489.	1.3	39

#	Article	IF	CITATIONS
19	C3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized non-human primates. Nature Communications, 2021, 12, 5456.	5.8	29
20	C3-targeted therapy in periodontal disease: moving closer to the clinic. Trends in Immunology, 2021, 42, 856-864.	2.9	27
21	Efficacy matters: broadening complement inhibition in COVID-19. Lancet Rheumatology, The, 2021, 3, e95.	2.2	6
22	Phase IIa clinical trial of complement C3 inhibitor AMY-101 in adults with periodontal inflammation. Journal of Clinical Investigation, 2021, 131, .	3.9	47
23	Air Bubbles Activate Complement and Trigger Hemostasis and C3-Dependent Cytokine Release Ex Vivo in Human Whole Blood. Journal of Immunology, 2021, 207, 2828-2840.	0.4	5
24	Complement C3 inhibition by compstatin Cp40 prevents intra- and extravascular hemolysis of red blood cells. Haematologica, 2020, 105, e57-e60.	1.7	17
25	Thirty-Eight-Negative Kinase 1 Is a Mediator of Acute Kidney Injury in Experimental and Clinical Traumatic Hemorrhagic Shock. Frontiers in Immunology, 2020, 11, 2081.	2.2	11
26	Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. Clinical Immunology, 2020, 220, 108598.	1.4	191
27	Current understanding of periodontal disease pathogenesis and targets for hostâ€modulation therapy. Periodontology 2000, 2020, 84, 14-34.	6.3	173
28	Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of age-related macular degeneration by restoring lysosomal function. Stem Cells Translational Medicine, 2020, 9, 1585-1603.	1.6	36
29	Interaction of Streptococcus pyogenes with extracellular matrix components resulting in immunomodulation and bacterial eradication. Matrix Biology Plus, 2020, 6-7, 100020.	1.9	1
30	The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clinical Immunology, 2020, 215, 108450.	1.4	252
31	Complement as a target in COVID-19?. Nature Reviews Immunology, 2020, 20, 343-344.	10.6	426
32	Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates. Clinical Immunology, 2020, 214, 108391.	1.4	16
33	Complement and tissue factor–enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. Journal of Clinical Investigation, 2020, 130, 6151-6157.	3.9	580
34	Soluble collectin-12 mediates C3-independent docking of properdin that activates the alternative pathway of complement. ELife, 2020, 9, .	2.8	15
35	Complement C3 as a Target of Host Modulation in Periodontitis. , 2020, , 13-29.		1
36	Clinical promise of next-generation complement therapeutics. Nature Reviews Drug Discovery, 2019, 18, 707-729.	21.5	253

#	Article	IF	CITATIONS
37	Cholesterol Crystals Induce Coagulation Activation through Complement-Dependent Expression of Monocytic Tissue Factor. Journal of Immunology, 2019, 203, 853-863.	0.4	31
38	Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS) Centroid Data Measured between 3.6 °C and 25.4 °C for the Fab Fragment of NISTmAb. Journal of Research of the National Institute of Standards and Technology, 2019, 124, 1-7.	0.4	3
39	â€~Stealth' corporate innovation: an emerging threat for therapeutic drug development. Nature Immunology, 2019, 20, 1409-1413.	7.0	7
40	Complement activation on neutrophils initiates endothelial adhesion and extravasation. Molecular Immunology, 2019, 114, 629-642.	1.0	15
41	C3 glomerulopathy — understanding a rare complement-driven renal disease. Nature Reviews Nephrology, 2019, 15, 129-143.	4.1	223
42	The Challenges and Promise of Complement Therapeutics for Ocular Diseases. Frontiers in Immunology, 2019, 10, 1007.	2.2	76
43	Interlaboratory Comparison of Hydrogen–Deuterium Exchange Mass Spectrometry Measurements of the Fab Fragment of NISTmAb. Analytical Chemistry, 2019, 91, 7336-7345.	3.2	44
44	New insights into the immune functions of complement. Nature Reviews Immunology, 2019, 19, 503-516.	10.6	281
45	Complementing the Cancer-Immunity Cycle. Frontiers in Immunology, 2019, 10, 774.	2.2	136
46	Complement-Dependent Mechanisms and Interventions in Periodontal Disease. Frontiers in Immunology, 2019, 10, 406.	2.2	60
47	Targeting Complement Pathways in Polytrauma- and Sepsis-Induced Multiple-Organ Dysfunction. Frontiers in Immunology, 2019, 10, 543.	2.2	47
48	Therapeutic targeting of the complement system. Nature Reviews Drug Discovery, 2019, , .	21.5	37
49	Taming hemodialysis-induced inflammation: Are complement C3 inhibitors a viable option?. Clinical Immunology, 2019, 198, 102-105.	1.4	11
50	Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule. Haematologica, 2019, 104, 919-928.	1.7	34
51	Reduced Terminal Complement Complex Formation in Mice Manifests in Low Bone Mass and Impaired Fracture Healing. American Journal of Pathology, 2019, 189, 147-161.	1.9	9
52	Protective Effects of the Complement Inhibitor Compstatin CP40 in Hemorrhagic Shock. Shock, 2019, 51, 78-87.	1.0	34
53	Editorial: Therapeutic Modulation of the Complement System: Clinical Indications and Emerging Drug Leads. Frontiers in Immunology, 2019, 10, 3029.	2.2	6
54	Innate immune responses to trauma. Nature Immunology, 2018, 19, 327-341.	7.0	377

#	Article	IF	CITATIONS
55	Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Seminars in Hematology, 2018, 55, 167-175.	1.8	32
56	Complement in cancer: untangling an intricate relationship. Nature Reviews Immunology, 2018, 18, 5-18.	10.6	279
57	Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression. Cancer Research, 2018, 78, 143-156.	0.4	94
58	Native state of complement protein C3d analysed via hydrogen exchange and conformational sampling. International Journal of Computational Biology and Drug Design, 2018, 11, 90.	0.3	6
59	Complement C5a-Mediated TAM-ing of Antitumor Immunity Drives Squamous Carcinogenesis. Cancer Cell, 2018, 34, 531-533.	7.7	4
60	Short Leucine-Rich Proteoglycans Modulate Complement Activity and Increase Killing of the Respiratory Pathogen <i>Moraxella catarrhalis</i> . Journal of Immunology, 2018, 201, 2721-2730.	0.4	10
61	Intravascular complement activation on neutrophils initiates the inflammatory cascade. Molecular Immunology, 2018, 102, 198.	1.0	Ο
62	Safety profile after prolonged C3 inhibition. Clinical Immunology, 2018, 197, 96-106.	1.4	38
63	Functional Relevance of the Anaphylatoxin Receptor C3aR for Platelet Function and Arterial Thrombus Formation Marks an Intersection Point Between Innate Immunity and Thrombosis. Circulation, 2018, 138, 1720-1735.	1.6	77
64	Novel Immunoassay for Complement Activation by PF4/Heparin Complexes. Thrombosis and Haemostasis, 2018, 118, 1484-1487.	1.8	7
65	The Complement System Is Critical in Maintaining Retinal Integrity during Aging. Frontiers in Aging Neuroscience, 2018, 10, 15.	1.7	61
66	Gingival Exudatome Dynamics Implicate Inhibition of the Alternative Complement Pathway in the Protective Action of the C3 Inhibitor Cp40 in Nonhuman Primate Periodontitis. Journal of Proteome Research, 2018, 17, 3153-3175.	1.8	24
67	New Analogs of the Complement C3 Inhibitor Compstatin with Increased Solubility and Improved Pharmacokinetic Profile. Journal of Medicinal Chemistry, 2018, 61, 6153-6162.	2.9	23
68	The renaissance of complement therapeutics. Nature Reviews Nephrology, 2018, 14, 26-47.	4.1	305
69	Differential capacity for complement receptorâ€mediated immune evasion by <i>Porphyromonas gingivalis</i> depending on the type of innate leukocyte. Molecular Oral Microbiology, 2017, 32, 154-165.	1.3	17
70	Structural Implications for the Formation and Function of the Complement Effector Protein iC3b. Journal of Immunology, 2017, 198, 3326-3335.	0.4	21
71	Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery. Trends in Immunology, 2017, 38, 383-394.	2.9	31
72	Complement C5a Functions as a Master Switch for the pH Balance in Neutrophils Exerting Fundamental Immunometabolic Effects. Journal of Immunology, 2017, 198, 4846-4854.	0.4	58

#	Article	IF	CITATIONS
73	Alginate microbeads are coagulation compatible, while alginate microcapsules activate coagulation secondary to complement or directly through FXII. Acta Biomaterialia, 2017, 58, 158-167.	4.1	17
74	Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy. Oncolmmunology, 2017, 6, e1326442.	2.1	48
75	Pericytes and immune cells contribute to complement activation in tubulointerstitial fibrosis. American Journal of Physiology - Renal Physiology, 2017, 312, F516-F532.	1.3	64
76	Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. Blood, 2017, 129, 970-980.	0.6	119
77	Method development and validation for the quantitation of the complement inhibitor Cp40 in human and cynomolgus monkey plasma by UPLC-ESI-MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1041-1042, 19-26.	1.2	8
78	Complement C3 inhibitor Cp40 attenuates xenoreactions in pigÂhearts perfused with human blood. Xenotransplantation, 2017, 24, e12262.	1.6	13
79	Factor H–IgG Chimeric Proteins as a Therapeutic Approach against the Gram-Positive Bacterial Pathogen <i>Streptococcus pyogenes</i> . Journal of Immunology, 2017, 199, 3828-3839.	0.4	26
80	Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10948-10953.	3.3	77
81	Complement receptors C5aR1 and C5aR2 act differentially during the early immune response after bone fracture but are similarly involved in bone repair. Scientific Reports, 2017, 7, 14061.	1.6	35
82	Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates. Molecular Therapy - Methods and Clinical Development, 2017, 6, 207-215.	1.8	33
83	Complement activation fragment C4a acts as effector molecule by signaling via protease-activated receptors 1 and 4. Molecular Immunology, 2017, 89, 130.	1.0	0
84	Complement C5aâ€Induced Changes in Neutrophil Morphology During Inflammation. Scandinavian Journal of Immunology, 2017, 86, 143-155.	1.3	58
85	<i>Porphyromonas gingivalis</i> disturbs host–commensal homeostasis by changing complement function. Journal of Oral Microbiology, 2017, 9, 1340085.	1.2	105
86	Novel mechanisms and functions of complement. Nature Immunology, 2017, 18, 1288-1298.	7.0	364
87	The effect of complement inhibition on erythrocyte destruction in AIHA. Molecular Immunology, 2017, 89, 203.	1.0	1
88	Regulator-dependent mechanisms of C3b processing by factor I allow differentiation of immune responses. Nature Structural and Molecular Biology, 2017, 24, 643-651.	3.6	106
89	Factor H C-Terminal Domains Are Critical for Regulation of Platelet/Granulocyte Aggregate Formation. Frontiers in Immunology, 2017, 8, 1586.	2.2	14
90	Coarse-Grained Conformational Sampling of Protein Structure Improves the Fit to Experimental Hydrogen-Exchange Data. Frontiers in Molecular Biosciences, 2017, 4, 13.	1.6	28

#	Article	IF	CITATIONS
91	Iron oxide nanoparticles induce cytokine secretion in a complement-dependent manner in a human whole blood model. International Journal of Nanomedicine, 2017, Volume 12, 3927-3940.	3.3	27
92	Complement component C3aR constitutes a novel regulator for chick eye morphogenesis. Developmental Biology, 2017, 428, 88-100.	0.9	8
93	From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Immunobiology, 2016, 221, 1046-1057.	0.8	14
94	Regulators of complement activity mediate inhibitory mechanisms through a common C3bâ€binding mode. EMBO Journal, 2016, 35, 1133-1149.	3.5	123
95	Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies. Molecular Therapy - Oncolytics, 2016, 3, 16027.	2.0	11
96	Complement in disease: a defence system turning offensive. Nature Reviews Nephrology, 2016, 12, 383-401.	4.1	427
97	Combined Inhibition of Complement and CD14 Attenuates Bacteria-Induced Inflammation in Human Whole Blood More Efficiently Than Antagonizing the Toll-like Receptor 4–MD2 Complex. Journal of Infectious Diseases, 2016, 214, 140-150.	1.9	13
98	Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application. Seminars in Immunology, 2016, 28, 285-291.	2.7	44
99	Structural insights into cofactor activity. Immunobiology, 2016, 221, 1193.	0.8	0
100	Mechanistic evidence for incomplete terminal pathway inhibition under eculizumab during strong complement activation. Immunobiology, 2016, 221, 1216.	0.8	0
101	Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia. Clinical Immunology, 2016, 171, 32-35.	1.4	23
102	High-Fat Diet-Induced Complement Activation Mediates Intestinal Inflammation and Neoplasia, Independent of Obesity. Molecular Cancer Research, 2016, 14, 953-965.	1.5	38
103	Complement therapeutics. Seminars in Immunology, 2016, 28, 205-207.	2.7	12
104	Systems Analysis of the Complement-Induced Priming Phase of Liver Regeneration. Journal of Immunology, 2016, 197, 2500-2508.	0.4	22
105	More than complementing Tolls: complement–Tollâ€like receptor synergy and crosstalk in innate immunity and inflammation. Immunological Reviews, 2016, 274, 233-244.	2.8	104
106	Protection of host cells by complement regulators. Immunological Reviews, 2016, 274, 152-171.	2.8	173
107	Preformed mediators of defense—Catekeepers enter the spotlight. Immunological Reviews, 2016, 274, 5-8.	2.8	4
108	Complement component C3 – The "Swiss Army Knife―of innate immunity and host defense. Immunological Reviews, 2016, 274, 33-58.	2.8	313

#	Article	IF	CITATIONS
109	Inhibition of preâ€existing natural periodontitis in nonâ€human primates by a locally administered peptide inhibitor of complement C3. Journal of Clinical Periodontology, 2016, 43, 238-249.	2.3	55
110	Control of the collective migration of enteric neural crest cells by the Complement anaphylatoxin C3a and N-cadherin. Developmental Biology, 2016, 414, 85-99.	0.9	22
111	New milestones ahead in complement-targeted therapy. Seminars in Immunology, 2016, 28, 208-222.	2.7	92
112	Properdin-Mediated C5a Production Enhances Stable Binding of Platelets to Granulocytes in Human Whole Blood. Journal of Immunology, 2016, 196, 4671-4680.	0.4	35
113	Using an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40. Clinical Immunology, 2016, 162, 37-44.	1.4	14
114	Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H–like Protein 1 Reveal Functional Determinants of Complement Regulation. Journal of Immunology, 2016, 196, 866-876.	0.4	37
115	Complement therapeutics in inflammatory diseases: promising drug candidates for C3â€ŧargeted intervention. Molecular Oral Microbiology, 2016, 31, 3-17.	1.3	36
116	Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. Immunobiology, 2016, 221, 503-511.	0.8	28
117	Therapeutic control of complement activation at the level of the central component C3. Immunobiology, 2016, 221, 740-746.	0.8	41
118	Complement inhibition decreases early fibrogenic events in the lung of septic baboons. Journal of Cellular and Molecular Medicine, 2015, 19, 2549-2563.	1.6	36
119	Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18. Thrombosis and Haemostasis, 2015, 114, 1207-1217.	1.8	38
120	Interventional treatment of renal angiomyolipoma: immediate results and clinical and radiological follow-up of 4.5 years. Acta Radiologica Open, 2015, 4, 205846011559244.	0.3	11
121	Complement Deficiency Promotes Cutaneous Wound Healing in Mice. Journal of Immunology, 2015, 194, 1285-1291.	0.4	58
122	PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer. Cell, 2015, 160, 700-714.	13.5	334
123	Neutrophil homeostasis and inflammation: novel paradigms from studying periodontitis. Journal of Leukocyte Biology, 2015, 98, 539-548.	1.5	96
124	Complement Inhibition in a Xenogeneic Model of Interactions Between Human Whole Blood and Porcine Endothelium. Hormone and Metabolic Research, 2015, 47, 36-42.	0.7	17
125	Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy. Immunobiology, 2015, 220, 993-998.	0.8	49
126	Inhibition of the alternative complement pathway preserves photoreceptors after retinal injury. Science Translational Medicine, 2015, 7, 297ra116.	5.8	58

#	Article	IF	CITATIONS
127	Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria. Blood, 2015, 126, 891-894.	0.6	89
128	Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters. Immunobiology, 2015, 220, 476-482.	0.8	58
129	Complement Inhibition Prevents Oncolytic Vaccinia Virus Neutralization in Immune Humans and Cynomolgus Macaques. Molecular Therapy, 2015, 23, 1066-1076.	3.7	65
130	Rare Loss-of-Function Mutation in Complement Component C3 Provides Insight into Molecular and Pathophysiological Determinants of Complement Activity. Journal of Immunology, 2015, 194, 3305-3316.	0.4	23
131	Regulation of Instant Blood Mediated Inflammatory Reaction (IBMIR) in Pancreatic Islet Xeno-Transplantation: Points for Therapeutic Interventions. Advances in Experimental Medicine and Biology, 2015, 865, 171-188.	0.8	25
132	Compstatin: a C3â€ŧargeted complement inhibitor reaching its prime for bedside intervention. European Journal of Clinical Investigation, 2015, 45, 423-440.	1.7	178
133	Complement Involvement in Periodontitis: Molecular Mechanisms and Rational Therapeutic Approaches. Advances in Experimental Medicine and Biology, 2015, 865, 57-74.	0.8	53
134	A Phase-Variable Surface Layer from the Gut Symbiont Bacteroides thetaiotaomicron. MBio, 2015, 6, e01339-15.	1.8	14
135	Applying complement therapeutics to rare diseases. Clinical Immunology, 2015, 161, 225-240.	1.4	60
136	Attenuation of <i>Staphylococcus aureus–</i> Induced Bacteremia by Human Mini-Antibodies Targeting the Complement Inhibitory Protein Efb. Journal of Immunology, 2015, 195, 3946-3958.	0.4	9
137	A 'rule of 3' to revive Greek science, research and innovation. Nature Immunology, 2015, 16, 1206-1208.	7.0	2
138	Acute Lung Injury and Fibrosis in a Baboon Model of <i>Escherichia coli</i> Sepsis. American Journal of Respiratory Cell and Molecular Biology, 2014, 50, 439-450.	1.4	30
139	T cell–derived interleukin (IL)-21 promotes brain injury following stroke in mice. Journal of Experimental Medicine, 2014, 211, 595-604.	4.2	85
140	Mouse genetics and proteomic analyses demonstrate a critical role for complement in a model of DHRD/ML, an inherited macular degeneration. Human Molecular Genetics, 2014, 23, 52-68.	1.4	47
141	The Extracellular Adherence Protein from <i>Staphylococcus aureus</i> Inhibits the Classical and Lectin Pathways of Complement by Blocking Formation of the C3 Proconvertase. Journal of Immunology, 2014, 193, 6161-6171.	0.4	51
142	Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. Expert Review of Hematology, 2014, 7, 583-598.	1.0	43
143	Conjugation to Albuminâ€Binding Molecule Tags as a Strategy to Improve Both Efficacy and Pharmacokinetic Properties of the Complement Inhibitor Compstatin. ChemMedChem, 2014, 9, 2223-2226.	1.6	13
144	The Role of Complement in Tumor Growth. Advances in Experimental Medicine and Biology, 2014, 772, 229-262.	0.8	155

#	Article	IF	CITATIONS
145	Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles. Biomaterials, 2014, 35, 3688-3696.	5.7	40
146	Crosstalk between the coagulation and complement systems in sepsis. Thrombosis Research, 2014, 133, S28-S31.	0.8	114
147	Do Cryopreserved Mesenchymal Stromal Cells Display Impaired Immunomodulatory and Therapeutic Properties?. Stem Cells, 2014, 32, 2430-2442.	1.4	300
148	The alternative complement pathway regulates pathological angiogenesis in the retina. FASEB Journal, 2014, 28, 3171-3182.	0.2	54
149	Post challenge inhibition of C3 and CD14 attenuates <i>Escherichia coli-</i> induced inflammation in human whole blood. Innate Immunity, 2014, 20, 68-77.	1.1	17
150	Cholesterol Crystals Induce Complement-Dependent Inflammasome Activation and Cytokine Release. Journal of Immunology, 2014, 192, 2837-2845.	0.4	236
151	A Murine Rp1 Missense Mutation Causes Protein Mislocalization and Slowly Progressive Photoreceptor Degeneration. American Journal of Pathology, 2014, 184, 2721-2729.	1.9	18
152	Genetic and Intervention Studies Implicating Complement C3 as a Major Target for the Treatment of Periodontitis. Journal of Immunology, 2014, 192, 6020-6027.	0.4	97
153	Porphyromonas gingivalis Manipulates Complement and TLR Signaling to Uncouple Bacterial Clearance from Inflammation and Promote Dysbiosis. Cell Host and Microbe, 2014, 15, 768-778.	5.1	318
154	Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood, 2014, 123, 2094-2101.	0.6	172
155	The Evolution and Appearance of C3 Duplications in Fish Originate an Exclusive Teleost c3 Gene Form with Anti-Inflammatory Activity. PLoS ONE, 2014, 9, e99673.	1.1	54
156	Distinct role of complement anaphylatoxin receptors C5aR and C3aR in obese adipose tissue inflammation and insulin resistance. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, .	0.6	1
157	Complement inhibition in cancer therapy. Seminars in Immunology, 2013, 25, 54-64.	2.7	121
158	Inhibition of biomaterialâ€induced complement activation attenuates the inflammatory host response to implantation. FASEB Journal, 2013, 27, 2768-2776.	0.2	35
159	Inducing and Characterizing Liver Regeneration in Mice: Reliable Models, Essential "Readouts―and Critical Perspectives. Current Protocols in Mouse Biology, 2013, 3, 141-170.	1.2	4
160	CMAP: Complement Map Database. Bioinformatics, 2013, 29, 1832-1833.	1.8	26
161	Complement in Immune and Inflammatory Disorders: Pathophysiological Mechanisms. Journal of Immunology, 2013, 190, 3831-3838.	0.4	412
162	The role of the complement system in metabolic organs and metabolic diseases. Seminars in Immunology, 2013, 25, 47-53.	2.7	126

#	Article	IF	CITATIONS
163	Complement in Immune and Inflammatory Disorders: Therapeutic Interventions. Journal of Immunology, 2013, 190, 3839-3847.	0.4	209
164	Does complement play a role in bone development and regeneration?. Immunobiology, 2013, 218, 1-9.	0.8	45
165	C5L2 receptor disruption enhances the development of diet-induced insulin resistance in mice. Immunobiology, 2013, 218, 127-133.	0.8	33
166	Progress and Trends in Complement Therapeutics. Advances in Experimental Medicine and Biology, 2013, 735, 1-22.	0.8	107
167	New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology, 2013, 218, 496-505.	0.8	129
168	Role of complement in host–microbe homeostasis of the periodontium. Seminars in Immunology, 2013, 25, 65-72.	2.7	75
169	Cholesterol crystals activate the complement system and are phagocytosed in a complement-dependent manner. Molecular Immunology, 2013, 56, 246.	1.0	1
170	C1-inhibitor efficiently inhibits <i>Escherichia coli</i> -induced tissue factor mRNA up-regulation, monocyte tissue factor expression and coagulation activation in human whole blood. Clinical and Experimental Immunology, 2013, 173, 217-229.	1.1	22
171	Complement in Action: An Analysis of Patent Trends from 1976 Through 2011. Advances in Experimental Medicine and Biology, 2013, 735, 301-313.	0.8	9
172	Complement-triggered pathways orchestrate regenerative responses throughout phylogenesis. Seminars in Immunology, 2013, 25, 29-38.	2.7	72
173	The induction of cytokines by polycation containing microspheres by a complement dependent mechanism. Biomaterials, 2013, 34, 621-630.	5.7	35
174	Autoregulation of thromboinflammation on biomaterial surfaces by a multicomponent therapeutic coating. Biomaterials, 2013, 34, 985-994.	5.7	50
175	Induction of Complement C3a Receptor Responses by Kallikrein-Related Peptidase 14. Journal of Immunology, 2013, 191, 3858-3866.	0.4	24
176	A Structurally Dynamic N-terminal Helix Is a Key Functional Determinant in Staphylococcal Complement Inhibitor (SCIN) Proteins. Journal of Biological Chemistry, 2013, 288, 2870-2881.	1.6	16
177	Complement anaphylatoxin C3a is a potent inducer of embryonic chick retina regeneration. Nature Communications, 2013, 4, 2312.	5.8	80
178	Complement modulates the cutaneous microbiome and inflammatory milieu. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 15061-15066.	3.3	138
179	The Complement Anaphylatoxin C5a Receptor Contributes to Obese Adipose Tissue Inflammation and Insulin Resistance. Journal of Immunology, 2013, 191, 4367-4374.	0.4	97
180	Rational Engineering of a Minimized Immune Inhibitor with Unique Triple-Targeting Properties. Journal of Immunology, 2013, 190, 5712-5721.	0.4	137

#	Article	IF	CITATIONS
181	Complement-Targeted Therapeutics in Periodontitis. Advances in Experimental Medicine and Biology, 2013, 735, 197-206.	0.8	17
182	The Effects of Selective Complement and CD14 Inhibition on the E. coli-Induced Tissue Factor mRNA Upregulation, Monocyte Tissue Factor Expression, and Tissue Factor Functional Activity in Human Whole Blood. Advances in Experimental Medicine and Biology, 2013, 735, 123-136.	0.8	20
183	Preclinical Development and In Vivo Evaluation Of Next-Generation Compstatin Analogs With Improved Systemic Profiles: A Novel Option For The Treatment Of Paroxysmal Nocturnal Hemoglobinuria. Blood, 2013, 122, 1239-1239.	0.6	1
184	Regulation of Immune Responsiveness In VivoÂby Disrupting an Early T-Cell Signaling Event Using a Cell-Permeable Peptide. PLoS ONE, 2013, 8, e63645.	1.1	7
185	Progress and trends in complement therapeutics. Advances in Experimental Medicine and Biology, 2013, 735, 1-22.	0.8	11
186	A sweet spot to control complement-induced inflammation. Nature Medicine, 2012, 18, 1340-1341.	15.2	6
187	C5a Receptor-Dependent Cell Activation by Physiological Concentrations of Desarginated C5a: Insights from a Novel Label-Free Cellular Assay. Journal of Immunology, 2012, 189, 4797-4805.	0.4	50
188	Correction: Protection of nonself surfaces from complement attack by factor h-binding peptides: implications for therapeutic medicine. Journal of Immunology, 2012, 188, 6425-6425.	0.4	2
189	Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression. Journal of Immunology, 2012, 189, 4674-4683.	0.4	219
190	Diversity in the C3b contact residues and tertiary structures of the staphylococcal complement inhibitor (SCIN) protein family Journal of Biological Chemistry, 2012, 287, 9329.	1.6	0
191	The Role of Properdin in Zymosan- and <i>Escherichia coli</i> -Induced Complement Activation. Journal of Immunology, 2012, 189, 2606-2613.	0.4	38
192	Diversity in the C3b Convertase Contact Residues and Tertiary Structures of the Staphylococcal Complement Inhibitor (SCIN) Protein Family. Journal of Biological Chemistry, 2012, 287, 628-640.	1.6	26
193	Platelets Contribute to the Pathogenesis of Experimental Autoimmune Encephalomyelitis. Circulation Research, 2012, 110, 1202-1210.	2.0	172
194	Local Complement-Targeted Intervention in Periodontitis: Proof-of-Concept Using a C5a Receptor (CD88) Antagonist. Journal of Immunology, 2012, 189, 5442-5448.	0.4	100
195	Immune competence of the Ciona intestinalis pharynx: Complement system-mediated activity. Fish and Shellfish Immunology, 2012, 33, 946-952.	1.6	34
196	Complement and dysbiosis in periodontal disease. Immunobiology, 2012, 217, 1111-1116.	0.8	97
197	Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis. Immunobiology, 2012, 217, 1097-1105.	0.8	39
198	Preface. Immunobiology, 2012, 217, 1025.	0.8	0

#	Article	IF	CITATIONS
199	Autoregulation of thromboinflammation on biomaterials and cells by a novel therapeutic coating technique. Immunobiology, 2012, 217, 1140.	0.8	0
200	Complement anaphylatoxin C5a supports ovarian cancer development and controls the expression of VEGF164/165 isoforms. Immunobiology, 2012, 217, 1155.	0.8	0
201	Complement in action: An analysis of patent trends from 1976 through 2011. Immunobiology, 2012, 217, 1157-1158.	0.8	0
202	Complement pathways in periodontitis and targeted therapeutic intervention. Immunobiology, 2012, 217, 1159.	0.8	0
203	Complement receptor C3aR modulates platelet function and thrombosis. Immunobiology, 2012, 217, 1160.	0.8	0
204	Compstatin induces allosteric changes in C3 and C3b and changes their ligand binding pattern. Immunobiology, 2012, 217, 1160.	0.8	0
205	On the conformational flexibility of C3b: A molecular insight into activation and transformation of a major complement effector. Immunobiology, 2012, 217, 1192.	0.8	0
206	Phagocytosis of Escherichia coli in human whole blood: Early complement dependency is succeeded by late CD14 dependency over time. Immunobiology, 2012, 217, 1193.	0.8	0
207	The role of properdin in zymosan- and Escherichia coli-induced complement activation. Immunobiology, 2012, 217, 1212.	0.8	0
208	Poly-cation containing alginate microcapsules induce cytokines by a complement-dependent mechanism. Immunobiology, 2012, 217, 1221.	0.8	3
209	Genetic and Pharmacologic Inhibition of Complement Impairs Endothelial Cell Function and Ablates Ovarian Cancer Neovascularization. Neoplasia, 2012, 14, 994-IN1.	2.3	103
210	A Complement–IL-4 Regulatory Circuit Controls Liver Regeneration. Journal of Immunology, 2012, 188, 641-648.	0.4	52
211	Absence of Mannose-Binding Lectin Prevents Hyperglycemic Cardiovascular Complications. American Journal of Pathology, 2012, 180, 104-112.	1.9	23
212	Pathogenic Microbes and Community Service Through Manipulation of Innate Immunity. Advances in Experimental Medicine and Biology, 2012, 946, 69-85.	0.8	43
213	Advances in Understanding the Structure, Function, and Mechanism of the SCIN and Efb Families of Staphylococcal Immune Evasion Proteins. Advances in Experimental Medicine and Biology, 2012, 946, 113-133.	0.8	31
214	C5aRâ€antagonist significantly reduces the deleterious effect of a blunt chest trauma on fracture healing. Journal of Orthopaedic Research, 2012, 30, 581-586.	1.2	41
215	Interactions between coagulation and complement—their role in inflammation. Seminars in Immunopathology, 2012, 34, 151-165.	2.8	393
216	Novel Complement Modulators for Paroxysmal Nocturnal Hemoglobinuria: Peptide and Protein Inhibitors of C3 Convertase Prevent Both Surface C3 Deposition and Subsequent Hemolysis of Affected Erythrocytes in Vitro. Blood, 2012, 120, 370-370.	0.6	0

#	Article	IF	CITATIONS
217	Low-Abundance Biofilm Species Orchestrates Inflammatory Periodontal Disease through the Commensal Microbiota and Complement. Cell Host and Microbe, 2011, 10, 497-506.	5.1	916
218	Complement Fragment C3a Controls Mutual Cell Attraction during Collective Cell Migration. Developmental Cell, 2011, 21, 1026-1037.	3.1	271
219	Synthesis and Activity of Thioether-Containing Analogues of the Complement Inhibitor Compstatin. ACS Chemical Biology, 2011, 6, 753-760.	1.6	70
220	Mesenchymal Stromal Cells Engage Complement and Complement Receptor Bearing Innate Effector Cells to Modulate Immune Responses. PLoS ONE, 2011, 6, e21703.	1.1	135
221	The Anaphylatoxin Receptor C5aR Is Present During Fracture Healing in Rats and Mediates Osteoblast Migration In Vitro. Journal of Trauma, 2011, 71, 952-960.	2.3	60
222	Microbial manipulation of receptor crosstalk in innate immunity. Nature Reviews Immunology, 2011, 11, 187-200.	10.6	256
223	Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency. Molecular Immunology, 2011, 48, 481-489.	1.0	62
224	Ornithodoros moubata complement inhibitor (OmCl) is an equally effective C5 inhibitor in pig and human, and combined with CD14 inhibition, efficiently attenuate Escherichia coli-induced sepsis in pigs. Molecular Immunology, 2011, 48, 1699.	1.0	0
225	Neisseria meningitidis and Escherichia coli are protected from leukocyte phagocytosis by binding to erythrocyte complement receptor 1 in human blood. Molecular Immunology, 2011, 48, 2159-2169.	1.0	20
226	G protein coupled receptor specificity for C3a and compound 48/80-induced degranulation in human mast cells: Roles of Mas-related genes MrgX1 and MrgX2. European Journal of Pharmacology, 2011, 668, 299-304.	1.7	98
227	Artificial Surface-Induced Inflammation Relies on Complement Factor 5: Proof From a Deficient Person. Annals of Thoracic Surgery, 2011, 91, 527-533.	0.7	17
228	Innate immunity activation on biomaterial surfaces: A mechanistic model and coping strategies. Advanced Drug Delivery Reviews, 2011, 63, 1042-1050.	6.6	163
229	Blood proteinâ€polymer adsorption: Implications for understanding complementâ€mediated hemoincompatibility. Journal of Biomedical Materials Research - Part A, 2011, 97A, 74-84.	2.1	48
230	Complement C3a and C5a modulate osteoclast formation and inflammatory response of osteoblasts in synergism with $IL\widehat{a} \in \widehat{d}^2$. Journal of Cellular Biochemistry, 2011, 112, 2594-2605.	1.2	142
231	Protection of Nonself Surfaces from Complement Attack by Factor H-Binding Peptides: Implications for Therapeutic Medicine. Journal of Immunology, 2011, 186, 4269-4277.	0.4	85
232	Immune Evasion of <i>Moraxella catarrhalis</i> Involves Ubiquitous Surface Protein A-Dependent C3d Binding. Journal of Immunology, 2011, 186, 3120-3129.	0.4	24
233	Early post-operative measurement of cytokine plasma levels combined with pre-operative bilirubin levels identify high-risk patients after liver resection. International Journal of Molecular Medicine, 2011, 27, 447-54.	1.8	18
234	PMX-53 as a Dual CD88 Antagonist and an Agonist for Mas-Related Gene 2 (MrgX2) in Human Mast Cells. Molecular Pharmacology, 2011, 79, 1005-1013.	1.0	89

#	Article	IF	CITATIONS
235	Activation of Polymorphonuclear Leukocytes by Candidate Biomaterials for an Implantable Glucose Sensor. Journal of Diabetes Science and Technology, 2011, 5, 1490-1498.	1.3	11
236	<i>Ornithodoros moubata</i> Complement Inhibitor Is an Equally Effective C5 Inhibitor in Pigs and Humans. Journal of Immunology, 2011, 187, 4913-4919.	0.4	40
237	The C5a Receptor Impairs IL-12–Dependent Clearance of <i>Porphyromonas gingivalis</i> and Is Required for Induction of Periodontal Bone Loss. Journal of Immunology, 2011, 186, 869-877.	0.4	149
238	Complement inhibition decreases the fibrotic response in septic baboons. FASEB Journal, 2011, 25, 114.7.	0.2	0
239	Abstract 2413: Diet-induced non-alcoholic steatohepatitis and hepatocellular carcinoma in chromosome substitution strains of mice. , 2011, , .		0
240	A complement receptor C5a antagonist regulates epithelial to mesenchymal transition and crystallin expression after lens cataract surgery in mice. Molecular Vision, 2011, 17, 949-64.	1.1	14
241	Hypoxia and reoxygenation of primary human hepatocytes induce proteome changes of glucose metabolism, oxidative protection and peroxisomal function. International Journal of Molecular Medicine, 2010, 26, 577-84.	1.8	14
242	Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood, 2010, 116, 4395-4403.	0.6	174
243	Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood, 2010, 116, 631-639.	0.6	124
244	Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood, 2010, 116, 1002-1010.	0.6	159
245	Key role of CD14 in the E. coli- and LPS-induced mRNA down regulation of the C5a receptors CD88 and C5L2. Molecular Immunology, 2010, 47, 2241-2241.	1.0	0
246	Characterization of the interactions between C3b and complement regulators. Molecular Immunology, 2010, 47, 2259-2259.	1.0	0
247	Murine visceral leishmaniasis: IgM and polyclonal Bâ€cell activation lead to disease exacerbation. European Journal of Immunology, 2010, 40, 1355-1368.	1.6	87
248	Multiâ€scale characterization of the energy landscape of proteins with application to the C3D/Efb complex. Proteins: Structure, Function and Bioinformatics, 2010, 78, 1004-1014.	1.5	5
249	Complementary Tolls in the periodontium: how periodontal bacteria modify complement and Toll-like receptor responses to prevail in the host. Periodontology 2000, 2010, 52, 141-162.	6.3	66
250	An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human blood. Gene Therapy, 2010, 17, 752-762.	2.3	36
251	Complement: a key system for immune surveillance and homeostasis. Nature Immunology, 2010, 11, 785-797.	7.0	2,990
252	Anti-inflammatory effects of C1-Inhibitor in porcine and human whole blood are independent of its protease inhibition activity. Innate Immunity, 2010, 16, 254-264.	1.1	12

#	Article	IF	CITATIONS
253	<i>In Vivo</i> Significance of ITK-SLP-76 Interaction in Cytokine Production. Molecular and Cellular Biology, 2010, 30, 3596-3609.	1.1	20
254	Complement Component C3 Binds to Activated Normal Platelets without Preceding Proteolytic Activation and Promotes Binding to Complement Receptor 1. Journal of Immunology, 2010, 184, 2686-2692.	0.4	100
255	Allosteric inhibition of complement function by a staphylococcal immune evasion protein. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 17621-17626.	3.3	77
256	Molecular Intercommunication between the Complement and Coagulation Systems. Journal of Immunology, 2010, 185, 5628-5636.	0.4	605
257	Microbial Hijacking of Complement–Toll-Like Receptor Crosstalk. Science Signaling, 2010, 3, ra11.	1.6	177
258	Structures of C3b in Complex with Factors B and D Give Insight into Complement Convertase Formation. Science, 2010, 330, 1816-1820.	6.0	241
259	Selective inhibition of TNF-α or IL-1β does not affect E. coli-induced inflammation in human whole blood. Molecular Immunology, 2010, 47, 1774-1782.	1.0	11
260	Contribution of chondroitin sulfate A to the binding of complement proteins to activated platelets. Molecular Immunology, 2010, 47, 2222-2222.	1.0	0
261	Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition?. Trends in Immunology, 2010, 31, 32-38.	2.9	119
262	Crosstalk pathways between Toll-like receptors and the complement system. Trends in Immunology, 2010, 31, 154-163.	2.9	248
263	Molecular Basis for Complement Recognition and Inhibition Determined by Crystallographic Studies of the Staphylococcal Complement Inhibitor (SCIN) Bound to C3c and C3b. Journal of Molecular Biology, 2010, 402, 17-29.	2.0	39
264	Suppression of Drusen Formation by Compstatin, a Peptide Inhibitor of Complement C3 activation, on Cynomolgus Monkey with Early-Onset Macular Degeneration. Advances in Experimental Medicine and Biology, 2010, 703, 127-135.	0.8	59
265	Contribution of Chondroitin Sulfate A to the Binding of Complement Proteins to Activated Platelets. PLoS ONE, 2010, 5, e12889.	1.1	42
266	A flow-through optical sensor system for label-free detection of proteins and DNA. , 2009, , .		1
267	Complement-Dependent Neutrophil Recruitment Is Critical for the Development of Elastase-Induced Abdominal Aortic Aneurysm. Circulation, 2009, 119, 1805-1813.	1.6	95
268	A Molecular Insight into Complement Evasion by the Staphylococcal Complement Inhibitor Protein Family. Journal of Immunology, 2009, 183, 2565-2574.	0.4	63
269	C3 Promotes Expansion of CD8+ and CD4+ T Cells in a <i>Listeria monocytogenes</i> Infection. Journal of Immunology, 2009, 183, 2921-2931.	0.4	42
270	The Regulation of Liver Cell Survival by Complement. Journal of Immunology, 2009, 182, 5412-5418.	0.4	91

#	Article	IF	CITATIONS
271	Human genetic deficiencies reveal the roles of complement in the inflammatory network: Lessons from nature. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 15861-15866.	3.3	119
272	Unwelcome Complement. Cancer Research, 2009, 69, 6367-6370.	0.4	50
273	Diet-induced hepatocellular carcinoma in genetically predisposed mice. Human Molecular Genetics, 2009, 18, 2975-2988.	1.4	142
274	Synergistic neuroprotective effects of C3a and C5a receptor blockade following intracerebral hemorrhage. Brain Research, 2009, 1298, 171-177.	1.1	75
275	Structureâ€kinetic relationship analysis of the therapeutic complement inhibitor compstatin. Journal of Molecular Recognition, 2009, 22, 495-505.	1.1	48
276	Complement and Neutrophil Function Changes After Liver Resection in Humans. World Journal of Surgery, 2009, 33, 2635-2643.	0.8	8
277	Crystallization of human complement component C3b in the presence of a staphylococcal complement-inhibitor protein (SCIN). Acta Crystallographica Section F: Structural Biology Communications, 2009, 65, 482-485.	0.7	10
278	C3a Receptor Antagonist Attenuates Brain Injury after Intracerebral Hemorrhage. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 98-107.	2.4	73
279	Structure of complement fragment C3b–factor H and implications for host protection by complement regulators. Nature Immunology, 2009, 10, 728-733.	7.0	299
280	Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nature Immunology, 2009, 10, 721-727.	7.0	205
281	Real-time label-free detection of complement activation products in human serum by white light reflectance spectroscopy. Biosensors and Bioelectronics, 2009, 24, 3359-3364.	5.3	17
282	Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends in Immunology, 2009, 30, 286-292.	2.9	123
283	Key role of complement receptor 1 in the initial binding of Escherichia coli and Neisseria meningitidis to erythrocytes in human whole blood. Molecular Immunology, 2009, 46, 2824.	1.0	0
284	Binding of complement proteins to activated platelets is independent of complement activation. Molecular Immunology, 2009, 46, 2853.	1.0	0
285	Preclinical evaluation of innate immunity to baculovirus gene therapy vectors in whole human blood. Molecular Immunology, 2009, 46, 2911-2917.	1.0	29
286	Recent developments in low molecular weight complement inhibitors. Molecular Immunology, 2009, 47, 185-195.	1.0	96
287	Complement Activation by CpG in a Human Whole Blood Loop System: Mechanisms and Immunomodulatory Effects. Journal of Immunology, 2009, 183, 6724-6732.	0.4	37
288	Dietâ€induced hepatocellular carcinoma in geneticallyâ€predisposed mice. FASEB Journal, 2009, 23, LB508.	0.2	0

#	Article	IF	CITATIONS
289	The artificial surfaceâ€induced whole blood inflammatory reaction revealed by increases in a series of chemokines and growth factors is largely complement dependent. Journal of Biomedical Materials Research - Part A, 2008, 87A, 129-135.	2.1	40
290	Solution insights into the structure of the Efb/C3 complement inhibitory complex as revealed by lysine acetylation and mass spectrometry. Journal of the American Society for Mass Spectrometry, 2008, 19, 55-65.	1.2	20
291	Development of a New Pharmacophore Model That Discriminates Active Compstatin Analogs. Chemical Biology and Drug Design, 2008, 72, 249-256.	1.5	11
292	Modulation of the antitumor immune response by complement. Nature Immunology, 2008, 9, 1225-1235.	7.0	612
293	Complement evasion by human pathogens. Nature Reviews Microbiology, 2008, 6, 132-142.	13.6	654
294	Complement activation triggered by chondroitin sulfate released by thrombin receptorâ€activated platelets. Journal of Thrombosis and Haemostasis, 2008, 6, 1413-1421.	1.9	127
295	Dissecting the instant bloodâ€mediated inflammatory reaction in islet xenotransplantation. Xenotransplantation, 2008, 15, 225-234.	1.6	121
296	ciCD94-1, an ascidian multipurpose C-type lectin-like receptor expressed in Ciona intestinalis hemocytes and larval neural structures. Differentiation, 2008, 76, 267-282.	1.0	26
297	Complexity of complement activation in sepsis. Journal of Cellular and Molecular Medicine, 2008, 12, 2245-2254.	1.6	109
298	Electrostatic contributions drive the interaction between <i>Staphylococcus aureus</i> protein Efb and its complement target C3d. Protein Science, 2008, 17, 1894-1906.	3.1	34
299	Complement Component C5a Mediates Hemorrhage-Induced Intestinal Damage. Journal of Surgical Research, 2008, 150, 196-203.	0.8	22
300	Dynamic structural changes during complement C3 activation analyzed by hydrogen/deuterium exchange mass spectrometry. Molecular Immunology, 2008, 45, 3142-3151.	1.0	19
301	Novel insights into target specificities and molecular mechanisms for two potent complement evasion proteins from Staphylococcus aureus. Molecular Immunology, 2008, 45, 4114-4115.	1.0	0
302	Genetic complement deficiencies dissociate the roles of human complement in the inflammatory responses: Lessons from nature. Molecular Immunology, 2008, 45, 4145-4146.	1.0	0
303	A C3 inhibitor on its way to clinical applications: Novel developments in compstatin activity and function. Molecular Immunology, 2008, 45, 4180.	1.0	0
304	Identification of complement-targeting peptides using phage-display libraries. Molecular Immunology, 2008, 45, 4180-4181.	1.0	1
305	C5a and TNF- \hat{l} ± Up-Regulate the Expression of Tissue Factor in Intra-Alveolar Neutrophils of Patients with the Acute Respiratory Distress Syndrome. Journal of Immunology, 2008, 180, 7368-7375.	0.4	115
306	Compstatin: A Complement Inhibitor on its Way to Clinical Application. Advances in Experimental Medicine and Biology, 2008, 632, 262-281.	0.8	139

#	Article	IF	CITATIONS
307	Interaction Between the Coagulation and Complement System. Advances in Experimental Medicine and Biology, 2008, 632, 68-76.	0.8	329
308	Cytokine Secretion Depends on Galα(1,3)Gal Expression in a Pig-to-Human Whole Blood Model. Journal of Immunology, 2008, 180, 6346-6353.	0.4	28
309	Cutting Edge: Members of the <i>Staphylococcus aureus</i> Extracellular Fibrinogen-Binding Protein Family Inhibit the Interaction of C3d with Complement Receptor 2. Journal of Immunology, 2008, 181, 7463-7467.	0.4	54
310	Stages of Meningococcal Sepsis Simulated In Vitro, with Emphasis on Complement and Toll-Like Receptor Activation. Infection and Immunity, 2008, 76, 4183-4189.	1.0	38
311	Ceruloplasmin/Hephaestin Knockout Mice Model Morphologic and Molecular Features of AMD. , 2008, 49, 2728.		117
312	Acute Antibody-Mediated Complement Activation Mediates Lysis of Pancreatic Islets Cells and May Cause Tissue Loss in Clinical Islet Transplantation. Transplantation, 2008, 85, 1193-1199.	0.5	73
313	Characterization of Ehp, a Secreted Complement Inhibitory Protein from Staphylococcus aureus. Journal of Biological Chemistry, 2007, 282, 30051-30061.	1.6	84
314	Complement Deposits on Ocular Tissues Adjacent to Sites of Inflammation. Current Eye Research, 2007, 32, 917-922.	0.7	14
315	C3a Is Required for the Production of CXC Chemokines by Tubular Epithelial Cells after Renal Ishemia/Reperfusion. Journal of Immunology, 2007, 178, 1819-1828.	0.4	104
316	Structure of Compstatin in Complex with Complement Component C3c Reveals a New Mechanism of Complement Inhibition. Journal of Biological Chemistry, 2007, 282, 29241-29247.	1.6	116
317	Regulation of Toll-like receptor–mediated inflammatory response by complement in vivo. Blood, 2007, 110, 228-236.	0.6	327
318	The Classical Complement Cascade Mediates CNS Synapse Elimination. Cell, 2007, 131, 1164-1178.	13.5	2,567
319	Complement and coagulation: strangers or partners in crime?. Trends in Immunology, 2007, 28, 184-192.	2.9	533
320	The role of complement in biomaterial-induced inflammation. Molecular Immunology, 2007, 44, 82-94.	1.0	384
321	DAF/Crry double deficiency in mice exacerbates nephrotoxic serum-induced proteinuria despite markedly reduced systemic complement activity. Molecular Immunology, 2007, 44, 139-146.	1.0	20
322	Structure–activity-based design of potent compstatin analogs. Molecular Immunology, 2007, 44, 192.	1.0	0
323	First identification of a chemotactic receptor in an invertebrate species: Structural and functional characterization of Ciona intestinalis C3a receptor. Molecular Immunology, 2007, 44, 238-239.	1.0	0
324	Effect of supraphysioloogic levels of C1-inhibitor on the classical, lectin, and alternative pathways of complement. Molecular Immunology, 2007, 44, 254.	1.0	0

#	Article	IF	CITATIONS
325	Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement. Molecular Immunology, 2007, 44, 1819-1826.	1.0	51
326	The C-terminus of complement factor H is essential for host cell protection. Molecular Immunology, 2007, 44, 2697-2706.	1.0	95
327	A novel complement evasion mechanism of Staphylococcus aureus using Efb. Molecular Immunology, 2007, 44, 3926.	1.0	0
328	The Role of Complement in Inflammatory Diseases From Behind the Scenes into the Spotlight. American Journal of Pathology, 2007, 171, 715-727.	1.9	563
329	New Approaches to the Treatment of Dense Deposit Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 2447-2456.	3.0	231
330	A simple, yet highly accurate, QSAR model captures the complement inhibitory activity of compstatin. Bioorganic and Medicinal Chemistry, 2007, 15, 1638-1644.	1.4	11
331	Complement-targeted therapeutics. Nature Biotechnology, 2007, 25, 1265-1275.	9.4	427
332	A structural basis for complement inhibition by Staphylococcus aureus. Nature Immunology, 2007, 8, 430-437.	7.0	148
333	CD59 Efficiently Protects Human NT2â€N Neurons Against Complementâ€mediated Damage. Scandinavian Journal of Immunology, 2007, 66, 345-351.	1.3	14
334	Conformational analysis of compstatin analogues with molecular dynamics simulations in explicit water. Journal of Molecular Graphics and Modelling, 2007, 26, 571-580.	1.3	12
335	Exploring the Complement Interaction Network Using Surface Plasmon Resonance. , 2007, 598, 260-278.		16
336	Ancient Origin of the Complement System: Emerging Invertebrate Models. , 2007, 598, 372-388.		45
337	Hydrogen/Deuterium Exchange Mass Spectrometry:Potential for Investigating Innate Immunity Proteins. , 2007, 598, 407-417.		6
338	Liver Regeneration: A Link to Inflammation through Complement. , 2006, 586, 17-34.		22
339	Hydrophobic Effect and Hydrogen Bonds Account for the Improved Activity of a Complement Inhibitor, Compstatin. Journal of Medicinal Chemistry, 2006, 49, 4616-4622.	2.9	100
340	To Regeneration with Complement. Advances in Experimental Medicine and Biology, 2006, 586, 63-70.	0.8	12
341	Liver inflammation and regeneration: Two distinct biological phenomena or parallel pathophysiologic processes?. Molecular Immunology, 2006, 43, 45-56.	1.0	82
342	Compstatin inhibits complement activation by binding to the β-chain of complement factor 3. Molecular Immunology, 2006, 43, 2023-2029.	1.0	25

#	Article	IF	CITATIONS
343	Expression of compstatin in Escherichia coli: Incorporation of unnatural amino acids enhances its activity. Protein Expression and Purification, 2006, 47, 289-295.	0.6	18
344	Generation of C5a in the absence of C3: a new complement activation pathway. Nature Medicine, 2006, 12, 682-687.	15.2	845
345	Structure of C3b reveals conformational changes that underlie complement activity. Nature, 2006, 444, 213-216.	13.7	344
346	A Protective Role for the Fifth Complement Component (C5) in Allergic Airway Disease. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 852-857.	2.5	48
347	Drusen complement components C3a and C5a promote choroidal neovascularization. Proceedings of the United States of America, 2006, 103, 2328-2333.	3.3	584
348	A Novel C5a Receptor-Tissue Factor Cross-Talk in Neutrophils Links Innate Immunity to Coagulation Pathways. Journal of Immunology, 2006, 177, 4794-4802.	0.4	412
349	Pathogenesis of B-Cell Superantigen-Induced Immune Complex-Mediated Inflammation. Infection and Immunity, 2006, 74, 1196-1203.	1.0	19
350	160. Innate Immune Responses to Viral Vectors Are Modulated by Complement Inhibitors in an Ex Vivo Model Using Whole Human Blood. Molecular Therapy, 2006, 13, S62-S63.	3.7	0
351	First Identification of a Chemotactic Receptor in an Invertebrate Species: Structural and Functional Characterization of <i>Ciona intestinalis</i> C3a Receptor. Journal of Immunology, 2006, 177, 4132-4140.	0.4	37
352	Cross-Disciplinary Research Stirs New Challenges into the Study of the Structure, Function and Systems Biology of Complement. Advances in Experimental Medicine and Biology, 2006, 586, 1-16.	0.8	4
353	The Role of Third Complement Component (C3) in Homing of Hematopoietic Stem/Progenitor Cells into Bone Marrow. , 2006, 586, 35-51.		20
354	A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. Journal of Clinical Investigation, 2006, 116, 783-796.	3.9	194
355	Thrombin as a C5 Convertase. FASEB Journal, 2006, 20, A641.	0.2	Ο
356	Structure-Based Integrative Computational and Experimental Approach for the Optimization of Drug Design. Lecture Notes in Computer Science, 2005, , 680-688.	1.0	10
357	Binding of C3 fragments on top of adsorbed plasma proteins during complement activation on a model biomaterial surface. Biomaterials, 2005, 26, 1477-1485.	5.7	171
358	C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. European Journal of Immunology, 2005, 35, 2496-2506.	1.6	125
359	A high-fat diet impairs liver regeneration in C57BL/6 mice through overexpression of the NF-κB inhibitor, IκBα. Hepatology, 2005, 42, 1148-1157.	3.6	125
360	Partial hepatectomy induced liver proteome changes in mice. Proteomics, 2005, 5, 318-325.	1.3	43

#	Article	IF	CITATIONS
361	Mechanisms of Action of Differentiation Inducers: Detection of Inducer Binding Protein(s) in Murine Erythroleukemia Cells. Oncology Research, 2005, 15, 21-37.	0.6	1
362	Electrostatic Modeling Predicts the Activities of Orthopoxvirus Complement Control Proteins. Journal of Immunology, 2005, 174, 2143-2151.	0.4	73
363	Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease): An Update. Journal of the American Society of Nephrology: JASN, 2005, 16, 1392-1403.	3.0	354
364	Solvent Accessibility of Native and Hydrolyzed Human Complement Protein 3 Analyzed by Hydrogen/Deuterium Exchange and Mass Spectrometry. Journal of Immunology, 2005, 174, 3469-3474.	0.4	26
365	Complement: An Inflammatory Pathway Fulfilling Multiple Roles at the Interface of Innate Immunity and Development. Inflammation and Allergy: Drug Targets, 2005, 4, 125-127.	3.1	24
366	The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. Journal of Experimental Medicine, 2005, 201, 567-577.	4.2	212
367	Complement Component C5a Is Integral to the Febrile Response of Mice to Lipopolysaccharide. NeuroImmunoModulation, 2005, 12, 67-80.	0.9	28
368	Design and NMR Characterization of Active Analogues of Compstatin Containing Non-Natural Amino Acids. Journal of Medicinal Chemistry, 2005, 48, 274-286.	2.9	68
369	Novel biological networks modulated by complement. Clinical Immunology, 2005, 115, 225-235.	1.4	42
370	Differential Effect of Heparin Coating and Complement Inhibition on Artificial Surface-Induced Eicosanoid Production. Annals of Thoracic Surgery, 2005, 79, 917-923.	0.7	30
371	Structure, Dynamics, Activity, and Function of Compstatin and Design of More Potent Analogues. , 2005, , 317-340.		4
372	Structure, Dynamics, Activity, and Function of Compstatin and Design of More Potent Analogues. , 2005, , 317-340.		3
373	Structure of the Anaphylatoxins C3a and C5a. , 2005, , 161-177.		Ο
374	The Building Blocks of the Complement System. , 2005, , 1-18.		1
375	Complement Activation Is Critical to Airway Hyperresponsiveness after Acute Ozone Exposure. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 726-732.	2.5	52
376	The Electrostatic Nature of C3d-Complement Receptor 2 Association. Journal of Immunology, 2004, 172, 7537-7547.	0.4	48
377	Complement C5a Receptor Is Essential for the Optimal Generation of Antiviral CD8+ T Cell Responses. Journal of Immunology, 2004, 173, 2524-2529.	0.4	97
378	Thermodynamic Studies on the Interaction of the Third Complement Component and Its Inhibitor, Compstatin. Journal of Biological Chemistry, 2004, 279, 54987-54995.	1.6	24

#	Article	IF	CITATIONS
379	C3a and C3b Activation Products of the Third Component of Complement (C3) Are Critical for Normal Liver Recovery after Toxic Injury. Journal of Immunology, 2004, 173, 747-754.	0.4	155
380	Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist. Journal of Neuroimmunology, 2004, 155, 55-63.	1.1	119
381	Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology, 2004, 325, 425-431.	1.1	115
382	Design of Peptide Analogues with Improved Activity Using a Novel de Novo Protein Design Approach. Industrial & Engineering Chemistry Research, 2004, 43, 3817-3826.	1.8	56
383	Dysregulation of Stathmin, a Microtubule-Destabilizing Protein, and Up-Regulation of Hsp25, Hsp27, and the Antioxidant Peroxiredoxin 6 in a Mouse Model of Familial Amyotrophic Lateral Sclerosis. American Journal of Pathology, 2004, 165, 1701-1718.	1.9	90
384	Physical methods for structure, dynamics and binding in immunological research. Trends in Immunology, 2004, 25, 700-707.	2.9	29
385	Novel monoclonal antibodies against mouse C3 interfering with complement activation: description of fine specificity and applications to various immunoassays. Molecular Immunology, 2004, 40, 1213-1221.	1.0	57
386	From atoms to systems: a cross-disciplinary approach to complement-mediated functions*1. Molecular Immunology, 2004, 41, 153-164.	1.0	10
387	Effect of complement inhibition and heparin coating on artificial surface–induced leukocyte and platelet activation. Annals of Thoracic Surgery, 2004, 77, 932-941.	0.7	68
388	A Functional C5a Anaphylatoxin Receptor in a Teleost Species. Journal of Immunology, 2004, 172, 349-355.	0.4	26
389	Improvement of the anti-C3 activity of compstatin using rational and combinatorial approaches. Biochemical Society Transactions, 2004, 32, 28-32.	1.6	34
390	Synthetic small-molecule complement inhibitors. Current Opinion in Investigational Drugs, 2004, 5, 1164-73.	2.3	28
391	Complement: Structure, Functions, Evolution, and Viral Molecular Mimicry. Immunologic Research, 2003, 27, 367-386.	1.3	53
392	Conformational interconversion in compstatin probed with molecular dynamics simulations. Proteins: Structure, Function and Bioinformatics, 2003, 53, 130-141.	1.5	23
393	Molecular cloning of the β subunit of complement component eight of rainbow trout. Developmental and Comparative Immunology, 2003, 27, 167-174.	1.0	34
394	Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3. Molecular Immunology, 2003, 39, 557-566.	1.0	81
395	C5a causes limited, polymorphonuclear cell-independent, mesenteric ischemia/reperfusion-induced injuryâ^†,â^†â^†. Clinical Immunology, 2003, 108, 263-273.	1.4	53
396	Restoration of Complement-Enhanced Neutralization of Vaccinia Virus Virions by Novel Monoclonal Antibodies Raised against the Vaccinia Virus Complement Control Protein. Journal of Virology, 2003, 77, 8256-8262.	1.5	27

#	Article	IF	CITATIONS
397	Expression of Complement 3 and Complement 5 in Newt Limb and Lens Regeneration. Journal of Immunology, 2003, 170, 2331-2339.	0.4	130
398	Complement Component 3 Is Required for Optimal Expansion of CD8 T Cells During a Systemic Viral Infection. Journal of Immunology, 2003, 170, 788-794.	0.4	105
399	The Proinflammatory Mediators C3a and C5a Are Essential for Liver Regeneration. Journal of Experimental Medicine, 2003, 198, 913-923.	4.2	385
400	Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Open Reading Frame 4 Protein (Kaposica) Is a Functional Homolog of Complement Control Proteins. Journal of Virology, 2003, 77, 3878-3881.	1.5	60
401	CiC3-1a-Mediated Chemotaxis in the Deuterostome Invertebrate <i>Ciona intestinalis</i> (Urochordata). Journal of Immunology, 2003, 171, 5521-5528.	0.4	76
402	Integrated Computational and Experimental Approach for Lead Optimization and Design of Compstatin Variants with Improved Activity. Journal of the American Chemical Society, 2003, 125, 8422-8423.	6.6	85
403	Protective Effects of IL-6 Blockade in Sepsis Are Linked to Reduced C5a Receptor Expression. Journal of Immunology, 2003, 170, 503-507.	0.4	301
404	Studies of Structure-Activity Relations of Complement Inhibitor Compstatin. Journal of Immunology, 2003, 171, 1881-1890.	0.4	39
405	Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1. Blood, 2003, 101, 3784-3793.	0.6	217
406	Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. Journal of Clinical Investigation, 2003, 112, 1644-1654.	3.9	266
407	Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. Journal of Clinical Investigation, 2003, 112, 1644-1654.	3.9	537
408	Protection of innate immunity by C5aR antagonist in septic mice. FASEB Journal, 2002, 16, 1567-1574.	0.2	152
409	Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 10837-10842.	3.3	417
410	Role of Membrane Cofactor Protein (CD46) in Regulation of C4b and C3b Deposited on Cells. Journal of Immunology, 2002, 168, 6298-6304.	0.4	123
411	Expression and Function of C5a Receptor in Mouse Microvascular Endothelial Cells. Journal of Immunology, 2002, 169, 5962-5970.	0.4	145
412	Herpes Simplex Virus Type 1 Evades the Effects of Antibody and Complement In Vivo. Journal of Virology, 2002, 76, 9232-9241.	1.5	91
413	Complement-mediated clearance of erythrocytes: mechanism and delineation of the regulatory roles of Crry and DAF. Blood, 2002, 100, 4544-4549.	0.6	44
414	Structural aspects and design of low-molecular-mass complement inhibitors. Biochemical Society Transactions, 2002, 30, 1026-1036.	1.6	49

#	Article	IF	CITATIONS
415	The complement system in teleosts. Fish and Shellfish Immunology, 2002, 12, 399-420.	1.6	511
416	Complement: more than a â€~guard' against invading pathogens?. Trends in Immunology, 2002, 23, 485-491.	2.9	144
417	Innate immunity in the Aegean: ancient pathways for today's survival. Developmental and Comparative Immunology, 2002, 26, 217-225.	1.0	14
418	The Structural Basis of Compstatin Activity Examined by Structure-Function-based Design of Peptide Analogs and NMR. Journal of Biological Chemistry, 2002, 277, 14942-14953.	1.6	50
419	Complement in urochordates: cloning and characterization of two C3-like genes in the ascidian Ciona intestinalis. Immunogenetics, 2002, 53, 1055-1064.	1.2	90
420	Kinetic Analysis of Glycoprotein C of Herpes Simplex Virus Types 1 and 2 Binding to Heparin, Heparan Sulfate, and Complement Component C3b. Virology, 2002, 294, 324-332.	1.1	68
421	Increased C5a receptor expression in sepsis. Journal of Clinical Investigation, 2002, 110, 101-108.	3.9	141
422	Increased C5a receptor expression in sepsis. Journal of Clinical Investigation, 2002, 110, 101-108.	3.9	103
423	Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood, 2002, 100, 1869-77.	0.6	342
424	Cloning and structure of three rainbow trout C3 molecules: a plausible explanation for their functional diversity. Developmental and Comparative Immunology, 2001, 25, 11-24.	1.0	76
425	Cloning and purification of the rainbow trout fifth component of complement (C5). Developmental and Comparative Immunology, 2001, 25, 419-430.	1.0	54
426	Phylogenetic aspects of the complement system. Developmental and Comparative Immunology, 2001, 25, 745-762.	1.0	118
427	Structural Studies in Solution of the Recombinant N-Terminal Pair of Short Consensus/Complement Repeat Domains of Complement Receptor Type 2 (CR2/CD21) and Interactions with Its Ligand C3dg. Biochemistry, 2001, 40, 5931-5941.	1.2	55
428	Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunological Reviews, 2001, 180, 35-48.	2.8	449
429	Epitope Mapping Using the X-Ray Crystallographic Structure of Complement Receptor Type 2 (CR2)/CD21: Identification of a Highly Inhibitory Monoclonal Antibody That Directly Recognizes the CR2-C3d Interface. Journal of Immunology, 2001, 167, 5758-5766.	0.4	49
430	Kinetic Analysis of the Interactions of Complement Receptor 2 (CR2, CD21) with Its Ligands C3d, iC3b, and the EBV Glycoprotein gp350/220. Journal of Immunology, 2001, 167, 1490-1499.	0.4	72
431	A Novel Role of Complement: Mice Deficient in the Fifth Component of Complement (C5) Exhibit Impaired Liver Regeneration. Journal of Immunology, 2001, 166, 2479-2486.	0.4	220
432	HUMAN SERUM-INDUCED EXPRESSION OF E-SELECTIN ON PORCINE AORTIC ENDOTHELIAL CELLS IN VITRO IS TOTALLY COMPLEMENT MEDIATED1. Transplantation, 2001, 72, 1967-1973.	0.5	24

#	Article	IF	CITATIONS
433	Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. Immunopharmacology, 2000, 49, 133-148.	2.0	147
434	Complement and innate immunity. Immunopharmacology, 2000, 49, 187-198.	2.0	112
435	Binding Kinetics, Structure-Activity Relationship, and Biotransformation of the Complement Inhibitor Compstatin. Journal of Immunology, 2000, 165, 2491-2499.	0.4	105
436	Novel Mechanism of Antibody-Independent Complement Neutralization of Herpes Simplex Virus Type 1. Journal of Immunology, 2000, 165, 4528-4536.	0.4	56
437	The three HveA receptor ligands, gD, LT-α and LIGHT bind to distinct sites on HveA. Molecular Immunology, 2000, 37, 665-673.	1.0	36
438	Modulation of fluid-phase complement activation inhibits hyperacute rejection in a porcine-to-human xenograft model. Transplantation Proceedings, 2000, 32, 899-900.	0.3	6
439	Inhibition of Heparin/Protamine Complex-Induced Complement Activation by Compstatin in Baboons. Clinical Immunology, 2000, 96, 212-221.	1.4	68
440	In Vivo Role of Complement-Interacting Domains of Herpes Simplex Virus Type 1 Glycoprotein Gc. Journal of Experimental Medicine, 1999, 190, 1637-1646.	4.2	108
441	Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 628-633.	3.3	149
442	Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. Xenotransplantation, 1999, 6, 52-65.	1.6	90
443	Contribution of the Innate Immune System to Autoimmune Diabetes: A Role for the CR1/CR2 Complement Receptors. Cellular Immunology, 1999, 195, 75-79.	1.4	36
444	Prolongation of ex vivo–perfused pig xenograft survival by the complement inhibitor compstatin. Transplantation Proceedings, 1999, 31, 934-935.	0.3	26
445	Inhibition of Herpes Simplex Virus gD and Lymphotoxin-α Binding to HveA by Peptide Antagonists. Journal of Virology, 1999, 73, 5681-5687.	1.5	13
446	Evolution and diversity of the complement system of poikilothermic vertebrates. Immunological Reviews, 1998, 166, 39-57.	2.8	155
447	Structure, functions, and evolution of the third complement component and viral molecular mimicry. Immunologic Research, 1998, 17, 109-121.	1.3	27
448	Solution structure of Compstatin, a potent complement inhibitor. Protein Science, 1998, 7, 619-627.	3.1	87
449	Complement diversity: a mechanism for generating immune diversity?. Trends in Immunology, 1998, 19, 519-523.	7.5	158
450	Cloning of three trout C3 isoforms: structural, functional, and phylogenetic analysis. Molecular Immunology, 1998, 35, 370.	1.0	3

#	Article	IF	CITATIONS
451	Expression of the third component of complement, C3, in regenerating limb blastema cells of urodeles. Molecular Immunology, 1998, 35, 372.	1.0	6
452	Inhibition of complement and xenogeneic endothelial cell activation by compstation. Molecular Immunology, 1998, 35, 372.	1.0	0
453	Mass spectrometric analysis of the activation and expression products of the third component of complement (C3). Molecular Immunology, 1998, 35, 373.	1.0	Ο
454	Herpes Simplex Virus Glycoprotein D Can Bind to Poliovirus Receptor-Related Protein 1 or Herpesvirus Entry Mediator, Two Structurally Unrelated Mediators of Virus Entry. Journal of Virology, 1998, 72, 7064-7074.	1.5	223
455	Compstatin Inhibits Complement and Cellular Activation in Whole Blood in Two Models of Extracorporeal Circulation. Blood, 1998, 92, 1661-1667.	0.6	133
456	Herpes Simplex Virus Type 1 Glycoprotein gC Mediates Immune Evasion In Vivo. Journal of Virology, 1998, 72, 8257-8263.	1.5	97
457	Structural and Antigenic Analysis of a Truncated Form of the Herpes Simplex Virus Glycoprotein gH-gL Complex. Journal of Virology, 1998, 72, 6092-6103.	1.5	68
458	The Chemistry and Biology of C3, C4 and C5. , 1998, , 83-118.		42
459	Compstatin Inhibits Complement and Cellular Activation in Whole Blood in Two Models of Extracorporeal Circulation. Blood, 1998, 92, 1661-1667.	0.6	6
460	Diversity of the third form of complement, C3, in fish: functional characterization of five forms of C3 in the diploid fish <i>Sparus aurata</i> . Biochemical Journal, 1997, 326, 877-881.	1.7	95
461	Differentiation-dependent changes in human trophoblast expression of decay-accelerating factor are modulated by 3?,5? cyclic adenosine monophosphate. Journal of the Society for Gynecologic Investigation, 1997, 4, 47-53.	1.9	4
462	Structural Change in α-Chymotrypsin Induced by Complexation with α1-Antichymotrypsin As Seen by Enhanced Sensitivity to Proteolysisâ€. Biochemistry, 1996, 35, 10608-10615.	1.2	81
463	Multiple forms of complement C3 in trout that differ in binding to complement activators Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 8546-8551.	3.3	141
464	Mass spectrometric analyses of the activation products of the third component of complement. Techniques in Protein Chemistry, 1996, 7, 81-91.	0.3	0
465	Immune evasion properties of herpes simplex virus type 1 glycoprotein gC. Journal of Virology, 1996, 70, 4253-4260.	1.5	96
466	The third component ofXenopus complement: cDNA cloning, structural and functional analysis, and evidence for an alternate C3 transcript. European Journal of Immunology, 1995, 25, 572-578.	1.6	29
467	Effect of a Putative B Cell Superantigen on Complement. Annals of the New York Academy of Sciences, 1995, 764, 356-358.	1.8	3
468	The Interaction of Glycoprotein C of Herpes Simplex Virus Types 1 and 2 with the Alternative Complement Pathway. Virology, 1994, 203, 299-312.	1.1	61

#	Article	IF	CITATIONS
469	Overexpression, purification, and characterization of third component of complement. Journal of Immunological Methods, 1994, 176, 127-139.	0.6	11
470	Phylogeny of the Third Complement Component, C3, and Conservation of C3-Ligand Interactions. Annals of the New York Academy of Sciences, 1994, 712, 354-357.	1.8	6
471	Hormonal regulation of complement components and receptors throughout the menstrual cycle. American Journal of Obstetrics and Gynecology, 1994, 170, 168-175.	0.7	78
472	Hormonal regulation of complement components and receptors throughout the menstrual cycle. American Journal of Obstetrics and Gynecology, 1994, 170, 168-175.	0.7	63
473	Expression of EBV/C3d receptors on T cells: biological significance. Trends in Immunology, 1993, 14, 56-59.	7.5	82
474	Hormonal Regulation of Complement Factor B in Human Endometrium. American Journal of Reproductive Immunology, 1993, 30, 63-67.	1.2	26
475	Conformational differences between surface-bound and fluid-phase complement-component-C3 fragments. Epitope mapping by cDNA expression. Biochemical Journal, 1992, 282, 715-721.	1.7	22
476	Phylogeny of the third component of complement, C3: Analysis of the conservation of human CR1, CR2, H, and B binding sites, concanavalin A binding sites, and thiolester bond in the C3 from different species. Developmental and Comparative Immunology, 1992, 16, 63-76.	1.0	63
477	Segment spanning residues 727-768 of the complement C3 sequence contains a neoantigenic site and accommodates the binding of CR1, factor H, and factor B. Biochemistry, 1992, 31, 1787-1794.	1.2	40
478	Interaction between Epstein-Barr virus and a T cell line (HSB-2) via a receptor phenotypically distinct from complement receptor type 2. European Journal of Immunology, 1992, 22, 1123-1131.	1.6	25
479	Evidence for multiple sites of interaction in C3 for complement receptor type 2 (C3d/EBV receptor,) Tj ETQq1 1 C).784314 rg 1.6	gBT_{45} /Overloc
480	Infection of human thymocytes by Epstein-Barr virus Journal of Experimental Medicine, 1991, 173, 971-980.	4.2	136
481	Neoantigens in complement component C3 as detected by monoclonal antibodies. Mapping of the recognized epitopes by synthetic peptides. Biochemical Journal, 1990, 268, 55-61.	1.7	31
482	Isolation and characterization of the third complement component of axolotl (Ambystoma) Tj ETQq0 0 0 rgBT /C 839-845.	overlock 10 0.2	Tf 50 227 To 5
483	Cell Surface Proteins Reacting with Activated Complement Components. Complement and Inflammation, 1989, 6, 142-165.	0.8	43
484	Minimum length of an idiotypic peptide and a model for its binding to a major histocompatibility complex class II molecule EMBO Journal, 1989, 8, 1947-1952.	3.5	69
485	The Central Segment of Herpes Simplex Virus Type 1 Glycoprotein C (gC) Is Not Involved in C3b Binding: Demonstration by Using Monoclonal Antibodies and Recombinant gC Expressed in Escherichia coli. Journal of General Virology, 1989, 70, 1571-1578.	1.3	23
486	Isolation of rat IgM to IgG hybridoma isotype switch variants and analysis of the efficiency of rat Ig in complement activation. European Journal of Immunology, 1989, 19, 131-135.	1.6	26

#	Article	IF	CITATIONS
487	Peptides of myelin basic protein stimulate T lymphocytes from patients with multiple sclerosis. Journal of Neuroimmunology, 1989, 22, 23-30.	1.1	39
488	A role for Lys-His-Gly-NH2 in avian and murine B cell development. Cellular Immunology, 1989, 122, 319-328.	1.4	23
489	Accumulation of viruslike particles in a yeast mutant lacking a mitochondrial pore protein Molecular and Cellular Biology, 1989, 9, 1100-1108.	1.1	38
490	Conservation of structural and functional domains in complement component C3 of Xenopus and mammals Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 1323-1327.	3.3	43
491	Acquired C1 inhibitor (C1-INH) deficiency type II. Replacement therapy with C1-INH and analysis of patients' C1-INH and anti-C1-INH autoantibodies Journal of Clinical Investigation, 1989, 83, 1794-1799.	3.9	59
492	Expression of CR2/EBV receptors on human thymocytes detected by monoclonal antibodies. European Journal of Immunology, 1988, 18, 1299-1302.	1.6	105
493	The multifunctional role of C3, the third component of complement. Trends in Immunology, 1988, 9, 387-393.	7.5	223
494	Functional maturation of murine B lymphocyte precursors—III. Soluble factors involved in the regulation of growth and differentiation. Molecular Immunology, 1988, 25, 1113-1127.	1.0	8
495	Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-CS antibodies. Molecular and Cellular Probes, 1987, 1, 141-149.	0.9	82
496	Similarities between a conserved sequence element of homoeo boxes and other genes. FEBS Letters, 1986, 194, 263-266.	1.3	2
497	Regulation of Human Cytotoxic Responses by Complement: C3, C3b and C3d Preparations Enhance Human Allogeneic Cytotoxic Responses. Immunopharmacology and Immunotoxicology, 1986, 8, 529-541.	1.1	5
498	The multifunctional role of C3: Structural analysis of its interactions with physiological ligands. Molecular Immunology, 1986, 23, 1237-1242.	1.0	23
499	Structural analysis of the asparagine-linked oligosaccharides of human complement component C3. Biochemical Journal, 1986, 233, 613-616.	1.7	75
500	Complement Receptors (CR) and Cytotoxic Responses: Monoclonal Antibodies Directed Against CR1 AMD CR3 Inhibit the Generation of Human Allospecific and Virus Specific Cytotoxic Cells in Vitro. Immunopharmacology and Immunotoxicology, 1986, 8, 75-88.	1.1	0
501	Structural and functional analysis of the complement component factor H with the use of different enzymes and monoclonal antibodies to factor H. Biochemical Journal, 1985, 232, 841-850.	1.7	93
502	Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 4235-4239.	3.3	98
503	Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b Journal of Clinical Investigation, 1985, 76, 1418-1426.	3.9	52
504	Lymphocyte mitogenesis induced by monoclonal antibodies to the T3 complex. Differential modulation by human IgG. Cellular Immunology, 1984, 89, 66-74.	1.4	20

#	Article	IF	CITATIONS
505	Mapping of the properdin-binding site in the third component of complement. Biochemical Journal, 1984, 217, 323-326.	1.7	32
506	Localization of the complement-component-C3b-binding site and the cofactor activity for factor I in the 38kDa tryptic fragment of factor H. Biochemical Journal, 1984, 224, 389-398.	1.7	116
507	Coupling of C3b to erythrocytes by disulfide bond formation: Preparation of EC3b for hemolytic and complement receptor assays. Journal of Immunological Methods, 1983, 65, 277-283.	0.6	13
508	Importance of Factors H and I for the Adherence of C3b-Coated Erythrocytes to Cells. Immunobiology, 1983, 165, 211-224.	0.8	3
509	Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 Fragments for Factors B and H, complement receptors , and bovine conglutinin. Journal of Experimental Medicine, 1983, 158, 334-352.	4.2	166
510	Identification of a C3bi-specific membrane complement receptor that is expressed on lymphocytes, monocytes, neutrophils, and erythrocytes. Journal of Experimental Medicine, 1982, 155, 96-110.	4.2	176
511	Activation of the Alternative Pathway of Human Complement by the Extracellular Slime Glycolipoprotein of Pseudomonas aeruginosa. Journal of Infectious Diseases, 1982, 145, 78-82.	1.9	10
512	Identification of three forms of iC3b that have distinct structures and receptor binding site properties. Molecular Immunology, 1982, 19, 1399.	1.0	4
513	Characterization of the lymphocyte membrane receptor for factor H (β1H- globulin) with an antibody to anti-factor H idiotype. Journal of Experimental Medicine, 1982, 155, 1400-1411.	4.2	61
514	In vivo changes in complement induced with peptidoglycan-polysaccharide polymers from streptococcal cell walls. Infection and Immunity, 1982, 35, 377-380.	1.0	29
515	Isolation of lymphocyte membrane complement receptor type two (the C3d receptor) and preparation of receptor-specific antibody Proceedings of the National Academy of Sciences of the United States of America, 1981, 78, 1828-1832.	3.3	71
516	Release of endogenous C3b inactivator from lymphocytes in response to triggering membrane receptors for beta 1H globulin Journal of Experimental Medicine, 1980, 152, 1625-1644.	4.2	137
517	Protein component of Pseudomonas aeruginosa slime glycolipoprotein in relation to laboratory-induced resistance to gentamicin. Canadian Journal of Microbiology, 1980, 26, 852-853.	0.8	1
518	A method for analysing lymphocyte surface antigens. Journal of Immunological Methods, 1980, 34, 287-293.	0.6	7
519	Fluorescent labelling of proteins of lymphocyte plasma membranes. Journal of Immunological Methods, 1979, 27, 55-59.	0.6	3
520	Complement as a target in COVID-19?. , 0, .		1
521	Complement Inhibitors Targeting C3, C4, and C5. , 0, , 75-112.		10